

## The complete non-invasive solution for advanced liver disease assessment



**FibroScan®**  
expert 630 by echosens

The complete non-invasive solution for advanced liver disease management

Expand clinical capabilities with spleen stiffness measurement and ultrasound localization system. Enhance exam efficiency with improved ergonomics and high-speed processing.

Powered by

**LSM® by VCTE™**

**Liver Fibrosis**

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment.

It is the standard for non-invasive evaluation of liver stiffness.\*

3,200+ peer-reviewed publications support the use of LSM by VCTE™.

**CAP™**

**Liver Steatosis**

CAP™ is unique, patented and validated for liver steatosis assessment.

900 international and peer-reviewed articles support the use of CAP™.

**SSM® by VCTE™**

**Portal hypertension**

SSM by VCTE™ is unique, patented and validated for portal hypertension assessment and can be used for risk stratification of patients with advanced CLD.†

It is a new marker for non-invasive evaluation of spleen stiffness.

110+ peer-reviewed publications support the use of SSM by VCTE™.

The new Bavaria VII guidelines confirm the value of using FibroScan® for the management of patients with advanced chronic hepatitis. It includes the measurement of spleen stiffness (SSM by VCTE™), with the first associated diagnosis thresholds.



What makes FibroScan® unique?

- Fast**  
A complete exam performed in less than 10 minutes to provide immediate results at the point of care.
- Intuitive**  
Can be performed by any trained operator (physician, nurse).
- Best in Class**  
The non-invasive gold standard solution validated by 2000+ peer-reviewed publications and 100 international guidelines.
- Reliable**  
Standardized examination with exceptional precision and reproducibility that can be achieved in 99% of patients.†
- Original**  
Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.

When evidence matters and consistency counts

- Pioneer in the field of elastography
- FibroScan® provides comprehensive liver disease and reports patients over time
- FibroScan® uses uniform algorithms that minimize inter-operator variability
- 4 clinical trials demonstrating high inter-operator variability
- 7,000+ FibroScan® installed worldwide enabling millions of liver examinations
- Winner of the Red Dot Design Award (FibroScan® 630 10th mode)



FibroScan® related solutions

**FibroScan® gateway**  
by echosens

Optimize clinical workflows with real-time secure data transmission

Save time, secure data, and improve patient follow-up with FibroScan® Gateway. FibroScan® Gateway acts as an integration engine, automatically uploading and storing examinations to the EHR (Electronic Health Record).



**Scores**  
by echosens

Enhancing FibroScan® liver disease assessment with biological markers

**Fast\***

Identification of at-risk NASH patients

**Agile 3+**

Identification of advanced fibrosis in NAFLD patients

**Agile 4**

Identification of cirrhosis in NAFLD patients

Your everyday FibroScan® companion

Assess your patient's liver health in just a few clicks



Available on myfibrosan.com or on the myFibroScan app



**FibroScan®**  
by echosens

The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan® is right for you?



Capabilities	FibroScan 630	FibroScan 630 Agile 3+	FibroScan 630 Agile 4	FibroScan 630 Gateway
LSM by VCTE™	✓	✓	✓	✓
CAP™	✓	✓	✓	✓
SSM by VCTE™	✓	✓	✓	✓
FibroScan® Gateway compatibility	✓	✓	✓	✓
MyFibroScan® compatibility	✓	✓	✓	✓
Embedded ultrasound localization system for assessment of obese or complex patients	✓	✓	✓	✓
High-speed processing	✓	✓	✓	✓
Integrated barcode reader	✓	✓	✓	✓
Versatile and adaptive design: from transportable to cart-based device with dedicated roll stand	✓	✓	✓	✓
Fully transportable	✓	✓	✓	✓
Battery-powered	✓	✓	✓	✓
Weight	5 kg	5 kg	10 kg	46 kg

\*Additional cost



because liver health matters

1. European Association for Study of Liver. Association Liver parameters are well defined. *Journal of Hepatology*. 2015;62(5):1023-1030. doi:10.1016/j.jhep.2015.03.026.  
 2. Carter R, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. *J Hepatol*. 2017;66(5):1025-1030. doi:10.1016/j.jhep.2016.12.022.  
 3. D'Amico G, et al. Interobserver concordance in controlled attenuation parameter measurement: a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. *Am J Gastroenterol*. 2012;107(10):1511-1516. doi:10.1038/ajg.2012.107.  
 4. D'Amico G, et al. Interobserver concordance in controlled attenuation parameter measurement by FibroScan® improves the accuracy of high-risk metabolic status. *Liver Int*. 2013;33(1):179-185. doi:10.1111/liv.12222.  
 Products in the FibroScan® range are Class II medical devices as defined by Directive 93/42/EEC (CE 0239). This device is designed for use in a medical practice in order to measure liver and spleen stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are strongly recommended to carefully read the instructions given in the user manual and on the labeling of these products. Check real device certificate with coding information: Agile 3+ and Agile 4 are in vitro diagnostic medical devices according to Directive 90/269/EEC. Agile 3+ and Agile 4 calculations are a tool for diagnosis. Real™ is computed from LSM and CAP (collected from FibroScan® device) and AST level (parameter measurement) to aid in the identification of a patient with suspicion of NAFLD as being at risk for extra-hepatic NAFLD (Diagnosis: NAFLD). Real™ was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Agile 3+ is computed from LSM (collected from FibroScan® device) and AST level (parameter measurement) to aid in the identification of a patient with suspicion of NAFLD as being at risk for extra-hepatic NAFLD (Diagnosis: NAFLD). Agile 3+ and Agile 4 were developed based on a prospective multicenter cohort and published in peer-reviewed literature. These scores are presented as an educational device intended for trained healthcare professionals. While these scores are about specific medical and health issues, they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as a basis for making individualized medical or health-related decisions. Echosens, All rights reserved. Echosens™, FibroScan®, among others, are trademarks and/or service marks of Echosens Group. FibroScan® Support 630 brochure v1022